Why Investors Have This Drug Makers' Stocks on Their Radar? - Carbylan Therapeutics, Catalent Inc., Medicines Co., and Diplomat Pharmacy

Jun 06, 2016, 08:00 ET from Chelmsford Park SA

NEW YORK, June 6, 2016 /PRNewswire/ --

The Generic Drugs space is an attractive yet very competitive industry. In today's lineup, ActiveWallSt.com have these companies: Carbylan Therapeutics Inc. (NASDAQ: CBYL), Catalent Inc. (NYSE: CTLT), The Medicines Co. (NASDAQ: MDCO), and Diplomat Pharmacy Inc. (NYSE: DPLO). Learn more about these stocks and receive your complimentary trade alerts at:


Last Friday at the close, shares in California-based specialty pharmaceutical Company, Carbylan Therapeutics Inc., surged 27.78% at $1.38. The stock recorded a trading volume of 6.79 million shares, which was higher than its three months average volume of 1.21 million shares. The Company's shares have advanced 86.49% in the last one month and 112.31% in the previous three months. The stock is trading above its 50-day moving average by 80.26%. Furthermore, shares of Carbylan Therapeutics have a Relative Strength Index (RSI) of 73.68. Free alert on CBYL can be accessed at:


Catalent Inc. offers advanced delivery technologies and development solutions for drugs, biologics, and consumer health products globally. The Company's stock finished Friday's session 0.19% higher at $26.35. A total volume of 1.50 million shares was traded, which was above their three months average volume of 1.03 million shares. The Company's shares have advanced 2.69% over the previous three months and 5.27% since the start of this year. The stock is trading below its 200-day moving average by 0.65%. Additionally, shares of Catalent have an RSI of 43.55. Sign up and activate your free alert on CTLT at:


Shares in The Medicines Co., which offers medicines for patients in acute and intensive care hospitals globally, ended the session 1.59% lower at $37.19 and with a total volume of 646,851 shares traded. The stock has gained 8.62% in the past month and 9.19% in the previous three months. The Company's shares are trading above their 50-day and 200-day moving averages by 7.28% and 4.11%, respectively. Moreover, shares of The Medicines Co. have an RSI of 59.58. Register for free on ActiveWallSt.com and activate your trade alert on MDCO at:


Flint, Michigan headquartered independent specialty pharmacy operator, Diplomat Pharmacy Inc.'s stock recorded a trading volume of 336,114 shares and closed the day 1.33% lower at $33.42. The Company's shares have gained 12.87% in the past month and 23.59% over the previous three months. The stock is trading 11.83% above its 50-day moving average and 6.02% above its 200-day moving average. Additionally, shares of Diplomat Pharmacy have an RSI of 66.23. DPLO free trade alert is just a click away at:


Active Wall Street: 

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

AWS has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/

CONTACT For any questions, inquiries, or comments reach out to us directly at: Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom Email: info@activewallst.com Phone number: 1-858-257-3144 CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA